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AT A SIMILAR MEETING in] une of 1966, also held at Brook 
Lodge, we presented data from more than 200 canine 
experiments which were designed (8, 26, 27) to deter-
mine: 1) what magnitude of immunosuppression could 
be expected in dogs from treatment with small volumes of 
antilymphocyte sera (ALS) possessing high antiwhite 
blood cell titers, 2) what were the toxic effects of this kind 
of therapy, and 3) what were acceptable methods by 
which the globulin derivative (ALG) of ALS could be 
used clinically. The way in which the results of the animal 
investigations were translated into a clinical treatment 
protocol was also discussed at the same conference 
based upon the first experience with human recipients of 
renal homografts who were treated with adjuvant horse 
immune globulin. 
Including these early patients, we have now given 
intramuscular ALG, in combination with azathioprine 
and prednisone, to about 140 recipients of kidneys, livers, 
or hearts. The injections have not been directly respon-
sible for any deaths. The benefits as well as the side effects 
of ALG have been analyzed from our case material on a 
number of occasions (11, 25, 27, 28) and will not be re-
peated here. Suffice it to say that after the addition of 
horse ALG to the therapeutic regimen in our institutions, 
the I-year survival after intrafamilial renal transplanta-
tion rose to more than 90 % and that after cadaveric renal 
transplantation to 83 %. In some of the liver recipients, of 
whom four have now lived for more than a year after 
operation, azathioprine was very greatly reduced and 
reliance was placed mainly on ALG and prednisone. 
Since ALG has been shown to be a potent immuno-
suppressive agent in every species including man in which 
it has been tested appropriately, there seems little reason 
to debate this issue in connection with organ transplanta-
tion in humans. However, a more legitimate inquiry has 
been raised by Hume et al. (7), namely, whether ALG is 
really needed in addition to azathioprine and prednisone 
for kidney transplantation, at least in their center. We 
will not dwell on this question since it has little to do with 
the points we wish to discuss here which are very simple 
and only three in number. 
I This study was supported by Public l-h'alth Service Grants 
AM-06344, AM-On72, FR-0005J, AI-04l52, FR-00069, AM-
12148, and AI-AM-08898. 
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IMMUNOSUPPRESSION OF AN ALS IN 
RELATION TO THE IMMUNIZING LYMPHOID ANTIGEN 
I t has often been speculated that an ALS with superior 
immunosuppressive qualities might be produced with 
special lymphoid antigen of some kind or other (2, 9, 16, 
21,30); the thymus gland and thoracic duct lymphocytes 
seem to have been sentimental favorites. 
Ono and his associates have been the only ones to 
formally examine this hypothesis (17). They raised ALS 
in New Zealand rabbits with identical doses and injection 
schedules of lymphocytes obtained from the spleens, 
thymus glands, and lymph nodes of inbred Fischer rats. 
The three different antisera all had exactly the same 
lymphoagglutinin (1: 1,000), and lymphocytotoxicity 
titers (l :512). The thromboagglutinin titers were the 
highest in the antispleen (l :64) and antithymus sera 
(l :32) and lowest in the antilymph node serum (l: 16). 
This was explained by the fact that the injections of the 
splenic and thymic lymphocytes had been more heavily 
contaminated with rat thrombocytes than was the case 
with the immunizing lymph node cell preparations. 
When the different kinds of rabbit antisera were 
injected intra peritoneally in rats, almost precisely the 
same degree of lymphopenia was produced. However, 
there was a difference in the side effect of thrombo-
cytopenia. This was minor with the sera raised with 
lymph node lymphocytes, but it was moderately severe 
with both the antispleen and anti thymus sera. The 
thrombocytopenic effect could be readily removed from 
the latter ALS preparations by absorption with rat 
platelets. The lymphopenic and immunosuppressive ef-
fects were not thereby reduced. 
The ability of the three different kinds of ALS to pre-
vent rejection was assessed in a model which permitted 
very precise delineation of results. The hearts of adult 
Wistar-Furth rats (AgB 2/2) were transplanted to the 
abdornens of Fischer strain rats (AgB 1/1), anastomozing 
the graft aorta and pulmonary artery to the recipient 
aorta and inferior vena cava, respectively. There was no 
equivocation about the diagnosis of end-stage rejection 
since this was defined as the time when a palpable heart 
beat stopped and when organized electrical activity 
ceased as measured by the EKG. Control animals were 
given 1 ml normal rabbit serum intraperitoneally on 
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TABLE 1. Survival of rat heart allografts treated with rabbit antirat lymphoid cell sera 
Sera )l"umbcr Range (days) Mean SD (SE) (days) PValue of Grafts 
Spleen 10 28-41 (28,30, 30, 33, 33, 34, 33.9±3.9 (1.3 ) P < 0.001 
35, 37, 38, 41) 
Thymus 10 20-40 (20, 23, 24, 27, 33, 34, 31.3±6.7 (2.4) P < 0.001 
35, 38, 39, 40) 
Lymph node 10 27-46 (27,30,31,31,34,39, 36.4±6.3 (2.2) P < 0.001 
41,41,44,46) 
Normal rabbit serum 10 ~eR (9, 10, 10, II, 12, 12, 12.0±1.9 (0.7) 
13, 13, IS, IS) 
Recipient rats were given I ml of each serum on days 0, 2, and 5 intrapcritoneally. 
days 0, 2, and 5. The same therapeutic schedule was fol-
lowed with the three antisera. 
Across this strong histocompatibility barrier, the mean 
survival of the heart grafts was 12 days in the control 
animals. This was increased to more than a month by 
three injections of each of the antilymphoid scra (Table 
1). There was no significant difference in the outcome 
using the various immune sera. 
The conclusions from this study were straightforward. 
First, there was no special advantage of using any par-
ticular kind of lymphoid tissue for immunization, at least 
in terms of the ultimate immunosuppressive effect. 
Second, the undesirable thrombocytopenia produced by 
some of the antisera was related directly to the platelet 
contamination in the cell suspensions used for the im-
munization. Finally, most of the anti platelet activity 
could be removed by absorption procedures without 
perceptibly reducing the ability of the sera to mitigate 
rejection. 
Since absorption with platelets is a time consuming 
and expensive step in the commercial preparation of 
ALS, a preferable solution is to take special pains to re-
move the platelets as completely as possible from the cell 
suspensions administered to the heterologous serum 
donor. This has been accomplished in our laboratory 
with splenic antigen by filtration, by differential cen-
trifugation, and by other mechanical means. It may be 
that some degree of platelet depression must be accepted 
as the inherent penalty for high dose ALG treatment 
since studies from both Pichlmayr's laboratories (20) and 
our own (24) have shown some cross reactivity of platelets 
and lymphocytes to ALS. However, the data in Ono's 
study suggest that the predominant thrombocytopenic 
effect of an ALS is explicable by thromboagglutinins 
caused by platelets which were accidentally included 
with the immunizing lymphocytes. 
LOCALIZATION OF ALS ANTIBODIES 
In the immunized rabbit, there has been little dispute 
that the antiwhite cell antibodies and the immunosup-
pressive effect reside exclusively or nearly so in the gam-
ma-G globulin (10, 12--15, 29); the same apparently 
is true in the goat (12). However, horse ALS has been 
reported by several authors to have a greater spread of 
the activity within the 7S gamma-globulin during the 
first few months of lymphoid tissue administration (3, 8, 
10, 19, 20, 24). Moreover, at a later time, after 3-11 
months of immunization, Pichlmayr described a shift of 
the antiwhite cell antibodies to the IgM fraction (19). 
Because of the loss of immunosuppressive potency of 
highly refined equine IgG that has been reported (4,24), 
Kashiwagi (12) undertook a reevaluation of the antibody 
localization in horse ALS using a combination of analytic 
techniques that included column chromatography, 
electrophoresis, immunoelectrophoresis, determination of 
protein concentration, and measurement of antibody 
titers. 
The three horses studied by Kashiwagi had been im-
munized weekly with subcutaneous canine or human 
spleen cells for 6-9 weeks; they were considered to be 
"early" serum donors. The results were the same with 
the sera of all three animals. There were seven protein 
peaks (fractions) identifiable by chromatography. The 
Iymphocytotoxic activity was vcry heavily, if not ex-
clusively, concentrated in the IgG. This was particularly 
evident in the pooled fractions I and II (Fig. 1) in which 
only IgG was represented. The lymphocytotoxins in the 
fractions III and IV were probably also contained in the 
IgG which contributed to these heterogenous collections. 
In contrast, more than 80 % of the leukoagglutinins 
were in the fractions III and IV (T-equine globulin) 
which consisted predominantly of IgA (also known as 
"fast" gamma-G, IgG (T». The hemagglutinins and 
thromboagglutinins were mostly in the same location, 
although these antibodies werc also detectable in the IgG 
(Fig. 1). 
The differential ammonium sulfate precipitation of 
Allen (1) was used to obtain bulk quantities of two horse 
antidog lymphocyte globulins (ALG). One, called frac-
tion G, had a high concentration of IgG. The other 
which was considerably more heterogenous was termed 
fraction T; its principal immunoglobulin was IgA. Before 
testing fraction G, it was diluted to give the same gamma-
globulin concentration as in the original ALS. A similar 
adjustment was made for the T-equine content offraction 
T. 
The protein concentrations and the antibody titers of 
the adjusted fractions are shown in Table 2, as well as 
the results obtained by subcutaneously giving 0.5 ml/kg 
per day of these substances to mongrel canine recipients 
of nonrelatcd kidney transplants. Treatment was started 
the day bcfore operation. The survival was prolonged 
under therapy with the ALS and the fractions G and T 
rcmoved from it. There seemed to be no difference using 
ALS and fraction T (P > 0.1) whereas the animals 
injected with fraction G lived for somewhat shorter 
periods (P < 0.01). 
-----------
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FIG. 1. Analysis of the location of antibodies in the serum of a different fractions. Alb, Albumin; at, alphal-globulin; a., alpha.-
horse that had been immunized for 6 weeks with weekly sub- globulin; a 2M, alpha2-macroglobulin; {3t, betal-globulin; {32, 
cutaneous injections of human splenic cells. Adjuvant was not beta2-globulin or T-equinc; 'Y, gamma-globulin; IgA, immuno-
used in this or any of the other heterologous serum donors. The globulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; 
multiple analytic techniques shown were used to determine the Tr, transferrin. 
varieties, concentrations, and activities of the proteins in the 
These studies have not weakened the proposition that 
most of the active portion of equine ALS is 7S gamma-
globulin in the first months after the beginning of 
immunization. However, they do provide a possible 
explanation for the loss of potency seen with highly 
refined horse IgG since this portion ("slow" gamma-G) 
represents only part of the total activity. The other 
portion consists of the "fast" gamma-G (IgA) so called 
because of its slightly greater electrophoretic mobility. 
The IgA, which is buried in the T-eguine globulin, is 
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TABLE 2. Results with canine renal Iransj)lanlalion using whole horse ALS or globulin fractions 
-------I--------------~I----------------- - ---- .- - - ---
1 Protein Concentration, g/IOO ml I Antibodies , I Survival ' P Value 
_K~-f No. i-·-. --~-----K---
Lympho- Hemag- Thrombo- Dogs! ]I; I To 1 To 
cytotoxin glutinin agglutinin .fean Range sE(I) Control ALS 
1
_-- -------1--
: T- I Betal,: ; Leukoa _ i 
I Gamma I equine I alpha, ~nd Total lutinD~ 
albumm I g I 
I I 
-.-.--- -~ -- 1----- --.--- .------
AbsorbedALS 11.7 1.6 3.8 17.1 1:2048 <0.01 1:512 I: 128 1:32 6 20.6 10-50 7.5 
Fraction G ·1 1.9 0.7 0.4 I 3.0 1:512 <0.01 <0.01 
Fraction T 0.7 1.6 2.6 i
1
4.9 1:2048 <0.01 1>0.1 
No treatment . 
Iii
1:512 I: 128 I: 16 10 16.3 9-34 3.3 
1:256 I: 128 1:32 10 19.4 11-35 3.3 
II 9.9 5-21 3.5 
--.-- -~---- --~-------------- ---- -,- -----, 
By concentration or dilution, it was attempted to give the fraction G injections the same gamma-globulin content as that in the 
ALS doses. A similar adjustment was made for the T-equine content of the fraction T. Note the high degree of contamination of 
the fraction T with extraneous protein. 
TABLE 3. Cases of new malignancy developing in 
recipients of renal homografts* 
Epithelia I Mesenchymal Total 
Total 6 9 15 
Azathioprine 6 9 15 
Prednisone 6 9 15 
ALG 0 3t 3 
* Eight cases have been reported in the literature (5, 6, 3, 
IS, 22, 23, 31). Details of the other cases were obtained by per-
sonal communication. t Woodruff's patient received ALG 
but only after the thoracic reticulum cell sarcoma was already 
visible on the chest X-ray. 
discarded in the process of refinement of IgG. Separation 
of the IgA from the other components of the hetero-
genous T-equine globulin and retention of it with the 
more easily reIllovable IgG is a practical problem which 
has not yet been solved satisfactorily for mass production. 
Parenthetically, the results suggest that distinct and 
different kinds of antibodies may contribute to the 
immunosuppressive effect of ALS. For example, the 
leukoagglutinins and lymphocytotoxins which seemed 
not to be in the same location, both appeared to be 
associated with the ability to mitigate graft rejection. 
IMMUNOSUPPRESSION AND ONCOGENESIS 
There have been several recent reports of malignant 
neoplasms developing in chronically surviving human 
recipients of renal homografts (5,6,18,22,31). In other 
publications (l8, 23) the ways have been discussed in 
which a number of factors present in the transplant 
recipient could have contributed to this situation. 
Furthermore, the connection between immunosuppres-
sion and new tumor growth in animals was the subject 
of several other communications in this Symposium. 
The only point which we wish to make is that there is 
little justification to implicate uniquely any of the special 
measures of immunosuppression including ALG which 
are in clinical use at the present time. This can be 
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